GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2008

Teva Plans to Acquire CoGenesys for $400M to Advance in the Biogenerics Field

  • Teva Pharmaceutical agreed to acquire CoGenesys for $400 million cash. Teva says that the purchase is an important springboard in the company’s efforts to become a leading player in the biogenerics market.

    “Biopharmaceuticals will be a long-term growth driver for Teva,” remarks Shlomo Yanai, Teva’s president and CEO. “CoGenesys’ acquisition reflects our commitment to capture the significant long-term prospects we believe the biogenerics market will offer.

    “CoGenesys’ breadth of technologies and the depth of their team and pipeline complement Teva’s large-scale operations, extensive resources, and its proven expertise in bringing drugs to market,” Yanai continues. “This combination will enable us to realize our vision of delivering high-quality, affordable biopharmaceuticals worldwide.”

    The transaction is expected to close during the first half of 2008.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?